Industry
Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 3:57 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 1:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:24 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 4:23 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 8:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 8:22 pm
Portfolio Pulse from Piero Cingari
July 18, 2024 | 8:59 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 2:58 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 6:59 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:34 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.